Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
Stem Cells Translational Medicine · 03.03.2023 · 12 (2) · 55-71
DOI: 10.1093/stcltm/szac086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 13.02.2023. Verfasst von Gabriela Sanchez-Petitto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Cord Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Transplantation of umbilical cord blood (UCB) is an attractive alternative source of hematopoietic stem cells (HSCs). The unique properties of cord blood and its distinct immune tolerance and engraftment kinetics compared to bone marrow (BM) and peripheral blood progenitor cells, permit a wider disparity in human leukocyte antigen levels between a cord blood donor and recipient after an unrelated umbilical cord blood transplant (UCBT). In addition, it is readily available and has a lowered risk of graft-versus-host disease (GvHD), with similar long-term clinical outcomes, compared to BM transplants. However, the relatively low number of cells administered by UCB units, as well as the associated delayed engraftment and immune reconstitution, pose limitations to the wide application of UCBT. Research into several aspects of UCBT has been evaluated, including the ex vivo expansion of cord blood HSCs and the process of fucosylation to enhance engraftment. Additionally, UCB has also been used in the treatment of several neurodegenerative and cardiovascular disorders with varying degrees of success. In this article, we will discuss the biology, clinical indications, and benefits of UCBT in pediatric and adult populations. We will also discuss future directions for the use of cord blood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Gabriela Sanchez-Petitto
Förderung
- NCI NIH HHS
Zitieren
APA
Sanchez-Petitto, G., Rezvani, K., Daher, M., Rafei, H., Kebriaei, P., Shpall, E. J., & Olson, A. (2023). Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Translational Medicine, 12(2), 55-71. https://doi.org/10.1093/stcltm/szac086
Vancouver
Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall EJ, et al. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Translational Medicine. 2023;12(2):55-71. doi:10.1093/stcltm/szac086
BibTeX
@article{SanchezPetitto2023,
author = {Sanchez-Petitto, Gabriela and Rezvani, Katayoun and Daher, May and Rafei, Hind and Kebriaei, Partow and Shpall, Elizabeth J and Olson, Amanda},
title = {Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future},
journal = {Stem Cells Translational Medicine},
year = {2023},
volume = {12},
number = {2},
pages = {55--71},
doi = {10.1093/stcltm/szac086}
}
EUVIMED